AR
Data & Repro
armored-cart-design-agent
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-SkillsView
Data & Repro
TU
tumor-mutational-burden-agent
Maintainer FreedomIntelligence · Last updated April 1, 2026
Compute TMB and assess its predictive value for immunotherapy response.
Original source
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/tumor-mutational-burden-agent
- Maintainer
- FreedomIntelligence
- License
- MIT
- Last updated
- April 1, 2026
Skill Snapshot
Key Details From SKILL.md
Key Notes
- The Tumor Mutational Burden Agent provides comprehensive TMB analysis for immunotherapy response prediction. It harmonizes TMB calculation across different assays, integrates with other biomarkers (PD-L1, MSI), and provides evidence-based therapy recommendations.
- When calculating TMB from panel sequencing, WES, or WGS data.
- To harmonize TMB values across different assay platforms.
- For predicting immunotherapy response using TMB and integrated biomarkers.
- When determining TMB-High status for pembrolizumab eligibility.
Source Doc
Excerpt From SKILL.md
Core Capabilities
-
TMB Calculation: Compute TMB from different sequencing platforms with appropriate normalization.
-
Platform Harmonization: Standardize TMB across FoundationOne, MSK-IMPACT, WES, and other assays.
-
TMB-High Classification: Apply FDA-approved and tumor-specific thresholds.
-
Biomarker Integration: Combine TMB with PD-L1, MSI, and gene signatures.
-
Response Prediction: ML models predicting ICI response from TMB-inclusive features.
-
Tumor-Specific Context: Interpret TMB relative to cancer type distributions.
TMB Calculation Methods
| Platform | Coverage | TMB Formula | Normalization |
|---|---|---|---|
| WES | 30-50 Mb | Nonsynonymous/coding Mb | Per exome size |
| FoundationOne | 1.1 Mb | Syn + nonsyn/panel Mb | FDA validated |
| MSK-IMPACT | 1.0-1.2 Mb | Nonsyn + splice/panel Mb | Panel-specific |
| TSO500 | 1.94 Mb | Coding mutations/Mb | Illumina validated |
| WGS | 3 Gb | Various metrics | Genome-wide |
TMB Thresholds
| Context | Threshold | Evidence |
|---|---|---|
| FDA (pan-tumor) | ≥10 mut/Mb | KEYNOTE-158 |
| Melanoma | ≥10 mut/Mb | Practice standard |
| NSCLC | ≥10 mut/Mb | Multiple trials |
| SCLC | ≥10 mut/Mb | Variable benefit |
| Colorectal (MSS) | Limited utility | MSI more predictive |
| Urothelial | ≥10 mut/Mb | IMvigor trials |
Use cases
- When calculating TMB from panel sequencing, WES, or WGS data.
Not for
- Do not rely on this catalog entry alone for installation or maintenance details.
Upstream Related Skills
- Variant_Annotation - For mutation calling
- Liquid_Biopsy_Analytics_Agent - For blood-based TMB
- Immune_Checkpoint_Combination_Agent - For ICI selection
Related skills
Related skills
AR
Data & Repro
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic search.
FreedomIntelligence/OpenClaw-Medical-SkillsView
AU
Data & Repro
autonomous-oncology-agent
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis generation.
FreedomIntelligence/OpenClaw-Medical-SkillsView
BI
Data & Repro
bio-cfdna-preprocessing
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-aware duplicate remo…
FreedomIntelligence/OpenClaw-Medical-SkillsView